CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage ...

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) had its price objective lowered by HC Wainwright from $14.00 to $11.00 ...

In recent trading, Reviva Pharmaceuticals Holdings Inc (RVPH) stock price has shown some volatility, fluctuating -19.80% over the last ...

H.C. Wainwright lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $11 from $14 and keeps a Buy rating on the shares. Johnson ...

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report)‘s stock had its “buy” rating restated by D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have ...

Reviva Pharmaceuticals Holdings Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 90.48%. The profit margin, also known as the revenue ratio or gross ...

Fintel reports that on January 10, 2025, Maxim Group upgraded their outlook for Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) from Hold to Buy. Analyst Price Forecast Suggests 724.68% Upside As ...

Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens ...

Fintel reports that on January 10, 2025, Roth MKM initiated coverage of Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) with a Buy recommendation. Analyst Price Forecast Suggests 729.09% Upside As ...

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory ...